On Demand CE - Treating High-Risk Patients with Dyslipidemia: Evidence and Challenges 

Latest in lipid treatment guidelines and challenges


In this hour-long webinar, you will learn the latest in high-risk dyslipidemia, including:
  • Differences and consistencies in the ACA/AHA and NLA guidelines.
  • Details regarding the use of PCSK9 Inhibitors in clinical practice, with a comparison of the two medications currently on the market.
  • A review of the groundbreaking Fourier and Odyssey outcomes trials.
  • Case studies in Familial Hyperlipidemia that demonstrate the application of lipid-lowering therapies in practice.

Credit: 1.0 CE contact hours, 0.5 pharmacology hours 
Cost: $0 for non-members and members 

Take this Course


  • Kathleen Byrne MSN, CRNP
Upon completion of this activity, participants will be able to: 
  • Compare available pharmacotherapies used to treat elevated LDL-C in high-risk patients.
  • Discuss the details of recent outcomes trials of PCSK9 inhibitors including value-related data.
  • Identify the current dyslipidemia guidelines and consensus statements to achieve LDL-C goal.
  • Provide professional- and patient-related strategies to improve patients access to new CVD therapies.
  • Illustrate, using case studies, treatment plans for LDL-C reduction in patients with FH and ASCVD.

Kathy Byrne
This educational activity is provided by the Preventive Cardiovascular Nurses Association (PCNA). PCNA is accredited by the American Association of Nurse Practitioners (AANP) as an approved provider of Nurse Practitioner continuing education, provider number 030602.